ARS Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue: | ||
| Product revenue, net | $7,763 | $— |
| Revenue under collaboration agreements | 210 | — |
| Total revenue | 7,973 | — |
| Operating expenses: | ||
| Cost of goods sold (including related party amounts of $488 and $0, respectively) | 1,094 | — |
| Research and development (including related party amounts of $666 and $726, respectively) | 2,952 | 5,234 |
| Selling, general and administrative (including related party amounts of $124 and $93, respectively) | 41,104 | 7,958 |
| Total operating expenses | 45,150 | 13,192 |
| Loss from operations | (37,177) | (13,192) |
| Other income, net | 3,237 | 2,900 |
| Net loss | $(33,940) | $(10,292) |
| Change in unrealized gains and losses on available-for-sale securities | (148) | (173) |
| Comprehensive loss | $(34,088) | $(10,465) |
| Net loss per share, basic and diluted | $(0.35) | $(0.11) |
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 98,060,636 | 96,486,480 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.